Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque

Revue Neurologique

Volumn 154, Issue 8-9, 1998, Pages 577-585

  Raine, C S ^a   Bonetti, B ^a,b   Cannella, B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b POLICLINICO BORGO ROMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; HUMAN; HUMAN TISSUE; LIGAND BINDING; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; SENILE PLAQUE; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; DEMYELINATING DISEASES; FAS LIGAND PROTEIN; HOMEOSTASIS; HUMANS; LIGANDS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; LYMPHOTOXIN-BETA; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031671153     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. ABASTADO J.P. (1996). Apoptosis: function and regulation of cell death. Res Immunol 147: 443-456.
2. BANNER D.W., D'ARCY A., JANES W., GENTZ R., SCHOENFELD H.H.J. (1993). Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73: 431-435.
3. BAZZONI F., BEUTLER B. (1995). How do tumor necrosis factor receptors work? J Inflamm.45: 221-238.
4. BEIDLER D.R., TEWARI M., FRIESEN P.D., POiRIER G., DIXIT V.M. (1995). The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem 270: 16526-16528.
5. BEUTLER B., VAN HUFFEL C. (1994). Unraveling function in the TNF ligand and receptor families. Science 264: 667-668.
6. BONETTI B., RAINE C.S. (1997). Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 42: 74-84.
7. BROSNAN C.F., RACKE M.K., SELMAJ K. (1997). An investigational approach to disease therapy in multiple sclerosis. In Raine CS, McFarland HF, Tourtellotte WW (eds). Multiple Sclerosis: Clinical and Pathogenetic Basis, pp. 325-340 Chapman and Hall, London.
8. BROSNAN C.F., RAINE C.S. (1996). Mechanisms of immune injury in multiple sclerosis. Brain Path 6: 243-257.
9. BROWNING J.L., DOUGAS I., NGAM-EK A., BOURDO P.R., EHRENFELS B.N., MIATKOWSKI K, ZAFARI M., YAMPAGLIA A.M., LAWTON P., MEIER W., BENJAMIN C.P., HESSION C. (1995). Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154: 33-46.
10. BROWNING J.L., NGAM-EK A., LAWTON P., DEMARINIS R., TIZARD R., CHOW E.P., HESSION C., O'BRINE G.B., FOLEY S.F., WARE C.F. (1993). Lymphotoxin ß, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-852.
11. CANNELLA B., RAINE C.S. (1995). The adhesion molecule/cytokine profile of multiple sclerosis lesions. Ann Neurol 27: 424-435.
12. CANNELLA B., SIZING I.D., BENJAMIN C.D., BROWNING J.L., RAINE C.S. (1997). Antibodies to lymphotoxin α (LTα) and LTß recognize different glial cell types in the central nervous system. J Neuroimmunol 18: 172-179.
13. CROWE P.D., VANARSDALE T.L., WALTER B.N., WARE C.F., HESSION C., EHRENFELS B., BROWNING J.L., DIN W.S., GOODWIN R.G., SMITH C.A. (1994). A lymphotoxin-(-specific receptor. Science 264: 707-710.
14. D'SOUZA S., ALINAUSKAS K., MCREA E., GOODYER C., ANTEL J.P. (1995). Differential susceptibility of human CNS-derived cell populations to TNF dependent and independent immune-mediated injury. J Neurosci 15: 7293-7300.
15. D'SOUZA S.D., BONETTI B., BALASINGAM V., CASHMAN N.R., BARKER P.A., TROUTT A.B., RAINE C.S., ANTEL J.P. (1996). Multiple Sclerosis: fas signaling in oligodendrocyte death. J Exp Med 184: 2362-2370.
16. DOWLING P., SHANG G., RAVAL S., MENONNA J., COOK S., HUSAR W. (1996). Involvement of the CD95 (APO-1, Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184: 1513-1518.
17. FONTANA A., FIERZ W., WEKERLE H. (1984). Astrocytes present myelin basic protein to encephalitogenic T cell lines. Nature 307: 273-276.
18. GHATAK N.R., LESHNER R.T., PRICE A.C., FELTEN W.L. (1989). Remyelination in the human central nervous system. J Neuropath Exp Neurol 48: 507-518.
19. HOFMAN F.M., HINTON D.R., JOHNSON K., MERRILL J.E. (1989). Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612.
20. ICHIKAWA H., OTA K., IWATA M. (1996). Increased Fas antigen on T cells in multiple sclerosis. J Neuroimmunol 71: 125-129.
21. KRATZ A., CAMPOS-NETO A., HANSO M.S., RUDDLE N.H. (1996). Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183: 1461-1472.
22. LEE S.C., MOORE G.R.W., GOLENWSKY G., RANE C.S. (1990). A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropath Exp Neurol 49: 122-136.
23. LUCCHINETTI C.F., BRUCK W., RODRIGUEZ M., LASSMANN H. (1996). Distinct patterns of multiple sclerosis pathology indicates heterogeneity of pathogenesis. Brain Path 6: 259-274.
24. MARSTERS S.A., FRUTKIN A.D., SIMPSON N.J., FENDLY B.M., ASHKENAZI A. (1990). Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem 265: 5747-5750.
25. MERRILL J.E. (1992). Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14: 1-10.
26. PAN G., O'ROURKE K., CHINNAIYAN A.M., GENTZ R., EBNER R., Ni J., DIXIT V.M. (1997). The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113.
27. PRINEAS J.W. (1997). Demyelinating diseases. In Graham DI, Lantos PL (eds.), Greenfield's Neuropathology, (Sixth Edition), pp.813-896. Arnold, London.
28. PRINEAS J.W., BARNARD R.O., KWON E.E., SHARER L.R., CHO E.S. (1993). Multiple sclerosis: Remyelination of nascent lesions. Ann Neurol 33: 137-151.
29. PRINEAS J.W., CONNELL F. (1978). The fine structure of chronically active multiple sclerosis plaques. Neurology 28: 68-75.
30. PRINEAS J.W., KWON E.E., GOLDENBERG P.Z., CHO E.S., SHARER L.R. (1990). Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions. Lab Invest. 63: 624-636.
31. PRINEAS J.W., KWON E.E., GOLDENBERG P.Z., ILYAS A.A., QUARLES R.H., BENJAMINS J.A., SPRINKLE T.J. (1989). Multiple sclerosis: Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 61: 489-503.
32. RAINE C.S. (1994) The Dale E. McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 36: 561-572.
33. RAINE C.S. (1995). Multiple Sclerosis: TNF revisited, with promise. Nature Med 1. 211-214.
34. RAINE C.S. (1997a). Demyelinating diseases. In Davis RL. Robertson DM (eds.), Textbook of Neuropathology (Third Edition), pp. 243-287. Williams & Wilkins, Baltimore.
35. RAINE C.S., (1997b). The Norton Lecture. A review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77: 135-152.
36. RAINE C.S., JOHNSON A.B., MARCUS D., SUZUKI A., BORNSTEIN M.B. (1981a). Demyelination in vitro: Absorption studies demonstrate that galactocerebroside is a major target. J Neurol Sci 52: 117-131.
37. RAINE C.S., SCHEINBERG L.C. (1988). On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol, 20: 189-201.
38. RAINE C.S., SCHEINBERG L.C., WALTZ J.M. (1981b). Multiple sclerosis: oligodendrocyte survival and proliferation in an active, established lesion. Lab Invest, 45: 534-546.
39. RAINE C.S., WU E. (1993). Multiple sclerosis: remyelination in acute lesions. J Neuropath Exp Neurol, 52: 199-205.
40. RENNERT P.D., BROWNING J.L., MEBIUS R., MACKAY F., HOCHMAN P.C. (1996). Surface lymphotoxin (( complex is required for the development of peripheral lymphoid organs. J Exp Med. 184: 1999-2006.
41. RIECKMANN P., ALBRECHT M., KITZE B., WEBER T., TUMANI H., BROOCKS A., LUER W., HELWIG A., POSER S. (1995). Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol, 37: 82-88.
42. ROTHWELL N.J., LUHESHI G.N. (1996). Brain TNF: damage lirnitation or damaged reputation? Nature Med, 2: 746-747.
43. SELMAJ K., RAINE C.S. (1988). Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol, 23: 339-346.
44. SELMAJ K., RAINE C.S., CANNELLA B., BROSNAN C.F. (1991a). Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 87: 949-954.
45. SELMAJ K., RAINE C.S., FAROOQ M., NORTON W.T., BROSNAN C.F. (1991b). Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol, 147: 1522-1529.
46. SELMAJ K.W. (1992). The role of cytokines in inflammatory conditions of the central nervous system. Sem Neurosci, 4: 221-229.
47. SHARIEF M.K., HENTGES R. (1991). Association between tumor necrosis factor-( and disease progression in chronic progressive multiple sclerosis N. Engl. J Med, 325: 467-472.
48. SUZUKI K., ANDREWS J.M., WALTZ J.M., TERRY R.D. (1969). Ultrastructural studies of multiple sclerosis. Lab Invest, 20: 444-454.
49. ULVESTAD E., WILLIAMS K., MORK S., ANTEL J.P., NYLAND H. (1994). Phenotypic differences between human monocytes/macrophages and microglial cells studied in situ and in vitro. J Neuropath Exp Neurol, 53: 492-501.
50. VANDANABEELE P., DEPERCQ W., BEYAERT R., FIERS W. (1995). Tumor necrosis factor receptors: structure and functions. Trends Biochem Sci, 5: 392-399.
51. VARTANIAN T., LI Y., ZHAO M., STEFANSSON K. (1995). Interferon-gamma induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med, 1: 732-743.
52. WILLIAMS K.C., ULVESTAD E., HICKEY W.F. (1994). Immunology of multiple sclerosis. Clin Neurosci, 2: 229-245.
53. WILT S.G., MILWARD E., ZHOU J.M., NAGASATO K., PATTON H., RUSTEN R., GRIFFIN D.E., O'CONNOR M., DUBOIS-DALCO M. (1995). In vitro evidence for a dual role for tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol, 37: 381-394.